The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
Research Article
[키워드] ACE2
acute respiratory syndrome
Ad5-hACE2
airway epithelia
angiotensin-converting enzyme 2
bind
Calu-3
camostat
Camostat mesylate
caused
Cell
cell line
cleaved
coronavirus
coronavirus disease
COVID-19
disease pathogenesis
entry of SARS-CoV-2
epithelia
exhibiting
greater
hACE2
host cell
human ACE2
in vivo
Infection
inhibit
inhibitors
initiate
intranasal
K18
K18-hACE2
limit
lung tissue
membrane fusion
MERS-CoV
mice
Middle East
Model
morbidity and mortality
Mortality
mouse
Mouse models
nafamostat
pandemic
pathogenic coronavirus
preclinical drug studies
primary human airway
Prophylactic
protease
Protease inhibitor
protease TMPRSS2
Protective
pulmonary
receptor
reduced
respiratory syndrome coronavirus
respiratory tract
SARS-CoV-2
SARS-COV-2 infection
serine protease
serine protease inhibitors
significantly
Spike protein
tested
the spike protein
TMPRSS2
transgenic mice
Treatment
viral burden
weight loss
[DOI] 10.1128/mBio.00970-21 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1128/mBio.00970-21 PMC 바로가기 [Article Type] Research Article